
NAUT
Nautilus Biotechnology Inc.
Company Overview
| Mkt Cap | $194.51M | Price | $2.24 |
| Volume | 252.95K | Change | +5.91% |
| P/E Ratio | -2.7 | Open | $2.19 |
| Revenue | -- | Prev Close | $2.12 |
| Net Income | $-70.8M | 52W Range | $0.62 - $2.54 |
| Div Yield | N/A | Target | $2.50 |
| Overall | 71 | Value | 60 |
| Quality | -- | Technical | 83 |
No chart data available
About Nautilus Biotechnology Inc.
Nautilus Biotechnology, Inc., a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome. The company develops Nautilus Platform, a proteomics platform that includes end-to-end solution comprised of instruments, consumables, and software analysis. It also offers proteome analysis system, a high-resolution optical imaging system with integrated fluidics and liquid handling sub-system designed to deposit protein libraries onto a flow cell and to process labeled multi-affinity reagent probe binding and imaging cycles rapidly to decode and quantify the proteins present in biological samples. In addition, the company offers reagent kits, which are comprised of sample preparation, flow cells, multi-affinity probe reagents, and instrument buffers system to perform multi-cycle analysis runs. Nautilus Biotechnology, Inc. was founded in 2016 and is headquartered in Seattle, Washington.
Latest News
Nautilus Biotechnology Regains Nasdaq Compliance
Nautilus Biotechnolgy (NAUT) Gets a Buy from TD Cowen
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | NAUT | $2.24 | +5.9% | 252.95K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |
Get Nautilus Biotechnology Inc. Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW